Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 36
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

  • Chamoun Huacon, Betty Odette
  • Torres Rodriguez, Irina Betsabe
  • Gabaldon Dominguez, Alejandra
  • Sellarés Roig, Joana
  • Perelló Carrascosa, Manel
  • Castella Fierro, Eva
  • Guri Azogue, Xavier
  • Salcedo Allende, Maria Teresa
  • Toapanta Gaibor, Nestor Gabriel
  • Cidraque Vella, Ignacio
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
Coeficient de variació; Biòpsies de protocol; Trasplantament renal, Coeficiente de variación; Biopsias de protocolo; Trasplante renal, Coefficient of variation; Protocol biopsies; Renal transplantation, The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C0), coefficient of variation of tacrolimus (CV-TAC-C0), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C0 at the time of biopsy as well as CV-TAC-C0, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C0 (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50–0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01–1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25–0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24–0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382), the Spanish Society of Transplantation and a Diaverum Spain restricted grant. Betty Chamoun has been supported by a VHIR (Vall Hebron Institute Research) grant.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19

  • Vergara Arana, Ander
  • Molina Van den Bosch, Mireia
  • Toapanta Gaibor, Nestor Gabriel
  • Villegas, Andrés
  • Sánchez-Cámara, Luis
  • Soler Romeo, Maria Jose
  • de Sequera, Patricia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiàlisi; Mortalitat, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiálisis; Mortalidad, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haemodialysis; Mortality, Age and chronic kidney disease have been described as mortality risk factors for coronavirus disease 2019 (COVID-19). Currently, an important percentage of patients in haemodialysis are elderly. Herein, we investigated the impact of age on mortality among haemodialysis patients with COVID-19. Data was obtained from the Spanish COVID-19 chronic kidney disease (CKD) Working Group Registry. From 18 March 2020 to 27 August 2020, 930 patients on haemodialysis affected by COVID-19 were included in the Registry. A total of 254 patients were under 65 years old and 676 were 65 years or older (elderly group). Mortality was 25.1% higher (95% CI: 22.2–28.0%) in the elderly as compared to the non-elderly group. Death from COVID-19 was increased 6.2-fold in haemodialysis patients as compared to the mortality in the general population in a similar time frame. In the multivariate Cox regression analysis, age (hazard ratio (HR) 1.59, 95% CI: 1.31–1.93), dyspnea at presentation (HR 1.51, 95% CI: 1.11–2.04), pneumonia (HR 1.74, 95% CI: 1.10–2.73) and admission to hospital (HR 4.00, 95% CI: 1.83–8.70) were identified as independent mortality risk factors in the elderly haemodialysis population. Treatment with glucocorticoids reduced the risk of death (HR 0.68, 95% CI: 0.48–0.96). In conclusion, mortality is dramatically increased in elderly haemodialysis patients with COVID-19. Our results suggest that this high risk population should be prioritized in terms of protection and vaccination., The authors are current recipients of FONDOS DE INVESTIGACIÓN SANITARIA—FEDER (ISCIII) PI17/00257, REDINREN RD16/0009/0030, RD/16/0009/0026, and EIN2020-112338.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience

  • Oleas, Diana
  • Bolufer Cardona, Monica
  • Agraz Pamplona, Irene
  • Gabaldon Dominguez, Alejandra
  • Bury, Roxana
  • Espinel Garuz, María Eugenia
  • Serón Micas, Daniel
  • García Carro, Clara
  • Soler Romeo, Maria Jose
  • Muñoz Couselo, Eva
  • Felip Font, Enriqueta
Nefritis intersticial aguda; Inhibidors de punts de control; Biòpsia de ronyó, Nefritis intersticial aguda; Inhibidores de puntos de control; Biopsia renal, Acute interstitial nephritis; Checkpoint inhibitors; Kidney biopsy, Background Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1–4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN). Methods We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d’Hebron University Hospital. Results In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250–500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease. Conclusions We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, ISCIII (PI17/00257) and Redinren (RD16/0009/0030). M.B. performed this work as the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR

  • Vergara Arana, Ander
  • Bermejo Garcia, Sheila
  • Azancot Rivero, M Antonieta
  • Sanchez Fructuoso, Ana Isabel
  • Sánchez de la Nieta, M. Dolores
  • Agraz Pamplona, Irene
  • Soler Romeo, Maria Jose
  • García-Carro, Clara
Malaltia renal crònica; Diabetis mellitus; Malaltia renal diabètica, Enfermedad renal crónica; Diabetes mellitus; Enfermedad renal diabética, Chronic kidney disease; Diabetes mellitus; Diabetic kidney disease, Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder—Instituto de Salud Carlos III (PI17/00257) and REDinREN (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
  • Barreira Diaz, Ana
  • Bermejo Garcia, Sheila
  • Suarez-Almazor, Maria
  • Bruera, Sebastian
Acute kidney injury; Immune checkpoint inhibitors; Immune-related hepatitis, Lesión renal aguda; Inhibidores del punto de control inmunitario; Hepatitis relacionada con el sistema inmunitario, Lesió renal aguda; Inhibidors del punt de control immunitari; Hepatitis associada a la immunitat, There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2–3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN (grant numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016) and Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR) enfermedades glomerulares complejas. Supported in part by the University of Texas MD Anderson’s Cancer Center Support Grant from the National Cancer Institute (NCI P30 CA016672).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

  • Bermejo Garcia, Sheila
  • Bolufer Cardona, Monica
  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
Chronic kidney disease; Dialysis; Immunotherapy, Enfermedad renal cronica; Diálisis; Inmunoterapia, Malaltia renal crònica; Diàlisi; Immunoteràpia, The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study

  • Bolufer Cardona, Monica
  • Blasco, Miquel
  • Quintana, Luis F
  • Rabasco, Cristina
  • Shabaka, Amir
  • García-Carro, Clara
Kidney biopsy; Renal pathology; Solid organ neoplasm, Biòpsia renal; Patologia renal; Neoplàsia d'òrgans sòlids, Biopsia renal; Patología renal; Neoplasia de órganos sólidos, Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histological characteristics of patients with active solid organ malignancy who underwent kidney biopsy. This is a multi-center collaborative retrospective study supported by groups GLOSEN/Onconephrology from the Spanish Society of Nephrology. Clinical, demographical and histological data were collected. Results: A total of 148 patients with cancer who underwent a kidney biopsy from 12 hospitals were included. 64.3% men and mean age of 66.9 years old. The indications for biopsy were acute renal injury (67.1%), proteinuria (17.1%), exacerbated chronic kidney disease (8.2%), and chronic kidney disease (7.5%). Most frequent malignances were lung (29.1%) and abdominal (25%), with 49.7% metastatic cancer. As oncospecific treatment, 28% received chemotherapy, 29.3% immunotherapy, 19.3% specific therapies, and 2.1% conservative treatment. At the time of kidney biopsy, median creatinine was of 2.58 mg/dL [1.81–4.1 (IQ 25–75)], median urine protein-to-creatinine ratio of 700 mg/g [256–2463 (IQ 25–75)] and 53.1% presented hematuria. The most frequent renal biopsy diagnoses were: acute interstitial nephritis (39.9%), acute tubular necrosis (8.8%), IgA nephropathy (7.4%) and membranous nephropathy (6.1%). Median follow-up was 15.2 months [5.7–31.4 (IQ 25–75)]. Conclusions: There is a new trend in kidney disease and cancer patients in terms of diagnosis and treatment. Acute interstitial nephritis has established itself as the most common kidney injury in patients with cancer who underwent a kidney biopsy. Renal biopsy is a valuable tool for diagnosis, treatment, and prognosis of solid organ cancer patients with kidney damage., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, Río Hortega CM20/00111, PI17/00257, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, and RD21/0005/0016 (RICORS 2040).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Kidney transplantation and COVID-19 renal and patient prognosis

  • Toapanta Gaibor, Nestor Gabriel
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Chamoun Huacon, Betty Odette
  • Serón Micas, Daniel
  • Moreso Mateos, Francesc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultat respiratòria aguda; Trasplantament renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultad respiratoria aguda; Trasplante renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Acute respiratory distress syndrome; Renal transplantation, Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030) and Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382). B.C. is supported by a Vall d’Hebron Institute of Research grant. This article is part of a supplement supported by Fresenius Medical Care without any influence on its content.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease

  • León Román, Juan
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Vergara Arana, Ander
  • Gabaldon Dominguez, Alejandra
  • Torres Rodriguez, Irina Betsabe
  • Bury, Roxana
  • Baldallo, Cinthia
  • Serón Micas, Daniel
  • Soler Romeo, Maria Jose
COVID-19; Malaltia renal crònica, COVID-19; Enfermedad renal crónica, COVID-19; Chronic kidney disease, Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Methods: Data included patients who underwent kidney biopsy at the Vall d’Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO­VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Conclusions: Patients with CO­VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder (FI17/00257 and EIN2020-1123381) and Redinren (RD16/0009/0030).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?

  • León Román, Juan
  • Agraz Pamplona, Irene
  • Vergara Arana, Ander
  • Toapanta Gaibor, Nestor Gabriel
  • García Carro, Clara
  • Gabaldon Dominguez, Alejandra
  • Roxana Bury Macias, Roxana Paola
  • Bermejo Garcia, Sheila
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
COVID-19; Nefritis tubulointersticial aguda; Biòpsia de ronyó, COVID-19; Nefritis tubulointersticial aguda; Biopsia de riñón, COVID-19; Acute tubulointerstitial nephritis; Kidney biopsy, Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AKI) is variable depending on several factors such as race/ethnicity and severity of illness. The pathophysiology of renal involvement in COVID-19 infection is not entirely clear, but it could be in part explained by the viral tropism in the kidney parenchyma. AKI in COVID-19 infection can be either by direct invasion of the virus or as a consequence of immunologic response. Diverse studies have focused on the effect of COVID-19 on glomerulonephritis (GN) patients or the ‘novo’ GN; however, the effect of COVID-19 in acute tubulointerstitial nephritis (ATIN) has been scarcely studied. In this article, we present five cases with different spectrums of COVID-19 infection and ATIN that may suggest that recent diagnosis of ATIN is accompanied by a worse clinical prognosis in comparison with long-term diagnosed ATIN., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant number PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Safety of Obtaining an Extra Biobank Kidney Biopsy Core

  • Bermejo Garcia, Sheila
  • García Carro, Clara
  • Mast, Richard
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • León Román, Juan
  • Bolufer Cardona, Monica
  • Gabaldon Dominguez, Alejandra
  • Serón Micas, Daniel
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
Biobank; Chronic kidney disease; Kidney biopsy, Biobanco; Enfermedad renal cronica; Biopsia renal, Biobanc; Malaltia renal crònica; Biòpsia de ronyó, Background and objectives: Kidney biopsy (KB) is the “gold standard” for the diagnosis of nephropathies and it is a diagnostic tool that presents a low rate of complications. Nowadays, biobank collections of renal tissue of patients with proven renal pathology are essential for research in nephrology. To provide enough tissue for the biobank collection, it is usually needed to obtain an extra kidney core at the time of kidney biopsy. The objective of our study is to evaluate the complications after KB and to analyze whether obtaining an extra core increases the risk of complications. Material and methods: Prospective observational study of KBs performed at Vall d’Hebron Hospital between 2019 and 2020. All patients who accepted to participate to our research biobank of native kidney biopsies were included to the study. Clinical and laboratory data were reviewed and we studied risk factors associated with complications. Results: A total of 221 patients were included, mean age 56.6 (±16.8) years, 130 (58.8%) were men, creatinine was 2.24 (±1.94) mg/dL, proteinuria 1.56 (0.506–3.590) g/24 h, hemoglobin 12.03 (±2.3) g/dL, INR 0.99 (±0.1), and prothrombin time (PT) 11.86 (±1.2) s. A total of 38 patients (17.2%) presented complications associated with the procedure: 13.1% were minor complications, 11.3% (n = 25) required blood transfusion, 1.4% (n = 3) had severe hematomas, 2.3% (n = 5) required embolization, and 0.5% (n = 1) presented arterio-venous fistula. An increased risk for complication was independently associated with obtaining a single kidney core (vs. 2 and 3 cores) (p = 0.021). Conclusions: KB is an invasive and safe procedure with a low percentage of complications. Obtaining an extra kidney core for research does not increase the risk of complications during the intervention, which remains low in concordance with previously published reports., The authors are current recipients of research grant from Red de Investigación Renal (REDINREN, RD16/0009/0030). (RICORS, RD21/0005/0016).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus

  • Torres, Armando|||0000-0003-1121-5173
  • Hernández, Domingo
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
  • Burgos, María Dolores
  • Pallardó, Luis M.
  • Kanter, Julia
  • Díaz-Corte, Carmen
  • Rodríguez, Minerva
  • Díaz Gómez, Juan Manuel|||0000-0002-5653-6619
  • Silva, Irene|||0000-0002-2723-1031
  • Valdes, Francisco
  • Fernández-Rivera, Constantino
  • Osuna, Antonio
  • Gracia Guindo, María C.
  • Gómez Alamillo, Carlos
  • Ruiz, Juan C.
  • Marrero Miranda, Domingo
  • Pérez-Tamajón, Lourdes
  • Rodríguez, Aurelio
  • González-Rinne, Ana
  • Alvarez, Alejandra
  • Perez-Carreño, Estefanía
  • de la Vega Prieto, María José
  • Henriquez, Fernando
  • Gallego Samper, Roberto
  • Salido, Eduardo
  • Porrini, Esteban
Despite the high incidence of posttransplant diabetes mellitus (PTDM) among high-risk recipients, no studies have investigated its prevention by immunosuppression optimization. We conducted an open-label, multicenter, randomized trial testing whether a tacrolimus-based immunosuppression and rapid steroid withdrawal (SW) within 1 week (Tac-SW) or cyclosporine A (CsA) with steroid minimization (SM) (CsA-SM), decreased the incidence of PTDM compared with tacrolimus with SM (Tac-SM). All arms received basiliximab and mycophenolate mofetil. High risk was defined by age.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation, The 2019 Expert Consensus From the Transplantion Society Working Group

  • Schinstock, Carrie A.|||0000-0002-3274-3277
  • Mannon, Roslyn B.|||0000-0003-1776-3680
  • Budde, K
  • Chong, Anita S.
  • Haas, Mark
  • Knechtle, Stuart
  • Lefaucheur, Carmen
  • Montgomery, Robert A.
  • Nickerson, Peter|||0000-0002-7393-7799
  • Tullius, Stefan G.
  • Ahn, Curie
  • Askar, Medhat
  • Crespo, Marta|||0000-0001-6992-6379
  • Chadban, Steven J.
  • Feng, Sandy
  • Jordan, Stanley C.
  • Man, Kwan
  • Mengel, Michael|||0000-0002-7222-3356
  • Morris, Randall E.
  • O'Doherty, Inish
  • Ozdemir, Binnaz H.
  • Seron, Daniel|||0000-0003-2054-653X
  • Tambur, Anat R.
  • Tanabe, Kazunari
  • Taupin, Jean-Luc
  • O'Connell, Philip J.
With the development of modern solid-phase assays to detect anti-HLA antibodies and a more precise histological classification, the diagnosis of antibody-mediated rejection (AMR) has become more common and is a major cause of kidney graft loss. Currently, there are no approved therapies and treatment guidelines are based on low-level evidence. The number of prospective randomized trials for the treatment of AMR is small, and the lack of an accepted common standard for care has been an impediment to the development of new therapies. To help alleviate this, The Transplantation Society convened a meeting of international experts to develop a consensus as to what is appropriate treatment for active and chronic active AMR. The aim was to reach a consensus for standard of care treatment against which new therapies could be evaluated. At the meeting, the underlying biology of AMR, the criteria for diagnosis, the clinical phenotypes, and outcomes were discussed. The evidence for different treatments was reviewed, and a consensus for what is acceptable standard of care for the treatment of active and chronic active AMR was presented. While it was agreed that the aims of treatment are to preserve renal function, reduce histological injury, and reduce the titer of donor-specific antibody, there was no conclusive evidence to support any specific therapy. As a result, the treatment recommendations are largely based on expert opinion. It is acknowledged that properly conducted and powered clinical trials of biologically plausible agents are urgently needed to improve patient outcomes.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

COVID-19 in CKD Patients, Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease

  • Román, Juan León
  • García-Carro, Clara|||0000-0002-5130-603X
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Vergara, Ander|||0000-0003-1926-0147
  • Gabaldón, Alejandra
  • Torres, Irina B.|||0000-0003-3304-0810
  • Bury, Roxana
  • Baldallo, Cinthia
  • Seron, Daniel|||0000-0003-2054-653X
  • Soler, María José|||0000-0003-3621-0766
Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Data included patients who underwent kidney biopsy at the Vall d'Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Patients with CO VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies, The Influence of TAC Exposure and Metabolism

  • Chamoun, Betty|||0000-0002-4267-2273
  • Torres, Irina B.|||0000-0003-3304-0810
  • Gabaldón, Alejandra
  • Sellarés Nadal, Joana
  • Perelló, Manel|||0000-0003-1859-5279
  • Castellà Fernández, Eva
  • Guri, Xavier
  • Salcedo, Maite
  • Toapanta, Néstor|||0000-0001-5983-6863
  • Cidraque, Ignacio
  • Moreso, Francesc|||0000-0002-7267-3963
  • Seron, Daniel|||0000-0003-2054-653X
The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C), coefficient of variation of tacrolimus (CV-TAC-C), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C at the time of biopsy as well as CV-TAC-C, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50-0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01-1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25-0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24-0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Matrix Metalloproteinases in Diabetic Kidney Disease

  • García Fernández, Nuria|||0000-0003-1082-0806
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Mora Gutiérrez, José María|||0000-0001-8537-5394
  • Vergara, Ander|||0000-0003-1926-0147
  • Orbe, Josune|||0000-0001-6300-7670
  • Soler, María José|||0000-0003-3621-0766
Around the world diabetic kidney disease (DKD) is the main cause of chronic kidney disease (CKD), which is characterized by mesangial expansion, glomerulosclerosis, tubular atrophy, and interstitial fibrosis. The hallmark of the pathogenesis of DKD is an increased extracellular matrix (ECM) accumulation causing thickening of the glomerular and tubular basement membranes, mesangial expansion, sclerosis, and tubulointerstitial fibrosis. The matrix metalloproteases (MMPs) family are composed of zinc-dependent enzymes involved in the degradation and hydrolysis of ECM components. Several MMPs are expressed in the kidney; nephron compartments, vasculature and connective tissue. Given their important role in DKD, several studies have been performed in patients with DKD proposing that the measurement of their activity in serum or in urine may become in the future markers of early DKD. Studies from diabetic nephropathy experimental models suggest that a balance between MMPs levels and their inhibitors is needed to maintain renal homeostasis. This review focuses in the importance of the MMPs within the kidney and their modifications at the circulation, kidney and urine in patients with DKD. We also cover the most important studies performed in experimental models of diabetes in terms of MMPs levels, renal expression and its down-regulation effect.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Transcriptome Analysis in Renal Transplant Biopsies Not Fulfilling Rejection Criteria

  • Moreso, Francesc|||0000-0002-7267-3963
  • Sellarès, Joana
  • Soler, María José|||0000-0003-3621-0766
  • Seron, Daniel|||0000-0003-2054-653X
The clinical significance of renal transplant biopsies displaying borderline changes suspicious for T-cell mediated rejection (TCMR) or interstitial fibrosis and tubular atrophy (IFTA) with interstitial inflammation has not been well defined. Molecular profiling to evaluate renal transplant biopsies using microarrays has been shown to be an objective measurement that adds precision to conventional histology. We review the contribution of transcriptomic analysis in surveillance and indication biopsies with borderline changes and IFTA associated with variable degrees of inflammation. Transcriptome analysis applied to biopsies with borderline changes allows to distinguish patients with rejection from those in whom mild inflammation mainly represents a response to injury. Biopsies with IFTA and inflammation occurring in unscarred tissue display a molecular pattern similar to TCMR while biopsies with IFTA and inflammation in scarred tissue, apart from T-cell activation, also express B cell, immunoglobulin and mast cell-related genes. Additionally, patients at risk for IFTA progression can be identified by genes mainly reflecting fibroblast dysregulation and immune activation. At present, it is not well established whether the expression of rejection gene transcripts in patients with fibrosis and inflammation is the consequence of an alloimmune response, tissue damage or a combination of both.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes

  • García-Carro, Clara|||0000-0002-5130-603X
  • Vergara, Ander|||0000-0003-1926-0147
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Jacobs-Cachá, Conxita|||0000-0003-2518-7847
  • Espinel Garuz, Eugenia
  • Seron, Daniel|||0000-0003-2054-653X
  • Soler, María José|||0000-0003-3621-0766
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Impact of HLA Mismatching on Early Subclinical Inflammation in Low-Immunological-Risk Kidney Transplant Recipients

  • Hernández, Domingo
  • Vázquez, Teresa
  • Alonso-Titos, Juana
  • León, Myriam
  • Caballero, Abelardo
  • Cobo, María Angeles
  • Sola, Eugenia|||0000-0002-9462-3342
  • López Jiménez, Verónica|||0000-0002-1793-7065
  • Ruiz-Esteban, Pedro
  • Cruzado, Josep María
  • Sellarés, Joana
  • Moreso, Francesc|||0000-0002-7267-3963
  • Manonelles, Anna|||0000-0003-2456-388X
  • Torio, Alberto
  • Cabello, Mercedes
  • Delgado-Burgos, Juan
  • Casas, Cristina
  • Gutiérrez, Elena
  • Jironda, Cristina
  • Kanter, Julia
  • Seron, Daniel|||0000-0003-2054-653X
  • Torres, Armando|||0000-0003-1121-5173
The impact of human leukocyte antigen (HLA)-mismatching on the early appearance of subclinical inflammation (SCI) in low-immunological-risk kidney transplant (KT) recipients is undetermined. We aimed to assess whether HLA-mismatching (A-B-C-DR-DQ) is a risk factor for early SCI. As part of a clinical trial (Clinicaltrials.gov, number NCT02284464), a total of 105 low-immunological-risk KT patients underwent a protocol biopsy on the third month post-KT. As a result, 54 presented SCI, showing a greater number of total HLA-mismatches (p = 0.008) and worse allograft function compared with the no inflammation group (48.5 ± 13.6 vs. 60 ± 23.4 mL/min; p = 0.003). Multiple logistic regression showed that the only risk factor associated with SCI was the total HLA-mismatch score (OR 1.32, 95%CI 1.06-1.64, p = 0.013) or class II HLA mismatching (OR 1.51; 95%CI 1.04-2.19, p = 0.032) after adjusting for confounder variables (recipient age, delayed graft function, transfusion prior KT, and tacrolimus levels). The ROC curve illustrated that the HLA mismatching of six antigens was the optimal value in terms of sensitivity and specificity for predicting the SCI. Finally, a significantly higher proportion of SCI was seen in patients with.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Treatment of early borderline lesions in low immunological risk kidney transplant patients, a Spanish multicenter, randomized, controlled parallel-group study protocol: the TRAINING study

  • Hernández, Domingo
  • Vázquez Sánchez, Teresa
  • Sola, Eugenia|||0000-0002-9462-3342
  • Lopez, Veronica
  • Ruiz-Esteban, Pedro
  • Caballero, Abelardo
  • Salido, Eduardo
  • León, Myriam
  • Rodriguez, Aurelio
  • Serra, Núria|||0000-0001-7926-2625
  • Rodríguez, Consuelo
  • Facundo, Carme|||0000-0003-1254-5553
  • Perello, Manel
  • Silva, Irene|||0000-0002-2723-1031
  • Marrero-Miranda, Domingo
  • Cidraque, Ignacio
  • Moreso, Francesc|||0000-0002-7267-3963
  • Guirado, Luis|||0000-0001-5119-3912
  • Seron, Daniel|||0000-0003-2054-653X
  • Torres, Armando|||0000-0003-1121-5173
Subclinical inflammation, including borderline lesions (BL), is very common (30-40%) after kidney transplantation (KT), even in low immunological risk patients, and can lead to interstitial fibrosis/tubular atrophy (IFTA) and worsening of renal function with graft loss. Few controlled studies have analyzed the therapeutic benefit of treating these BL on renal function and graft histology. Furthermore, these studies have only used bolus steroids, which may be insufficient to slow the progression of these lesions. Klotho, a transmembrane protein produced mainly in the kidney with antifibrotic properties, plays a crucial role in the senescence-inflammation binomial of kidney tissue. Systemic and local inflammation decrease renal tissue expression and soluble levels of α-klotho. It is therefore important to determine whether treatment of BL prevents a decrease in α-klotho levels, progression of IFTA, and loss of kidney function. The TRAINING study will randomize 80 patients with low immunological risk who will receive their first KT. The aim of the study is to determine whether the treatment of early BL (3rd month post-KT) with polyclonal rabbit antithymocyte globulin (Grafalon®) (6 mg/kg/day) prevents or decreases the progression of IFTA and the worsening of graft function compared to conventional therapy after two years post-KT, as well as to analyze whether treatment of BL with Grafalon® can modify the expression and levels of klotho, as well as the pro-inflammatory cytokines that regulate its expression. This phase IV investigator-driven, randomized, placebo-controlled clinical trial will examine the efficacy and safety of Grafalon® treatment in low-immunological-risk KT patients with early BL. : NCT04936282. Registered June 23, 2021, . Protocol Version 2 of 21 January 2022. Sponsor: Canary Isles Institute for Health Research Foundation, Canary Isles (FIISC). mgomez@fciisc.org.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events, Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
  • Barreira-Diaz, Ana|||0000-0002-4368-8939
  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bruera, Sebastian
  • Suarez-Almazor, Maria E.
There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2-3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease, Should We Individualize the Treatment?

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • Bolufer, Mónica|||0000-0002-3379-7031
  • Riveiro Barciela, Mar|||0000-0001-9309-2052
  • Soler, María José|||0000-0003-3621-0766
The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The coexistence of diabetic retinopathy and diabetic nephropathy is associated with worse kidney outcomes

  • Bermejo García, Sheila|||0000-0002-3611-4830
  • González, Ester
  • López-Revuelta, Katia
  • Ibernon, Meritxell
  • López, Diana
  • Martín-Gómez, Adoración
  • Garcia-Osuna, Rosa
  • Linares, Tania
  • Díaz Encarnación, Montserrat Mercedes|||0000-0001-5172-3370
  • Martín, Nàdia
  • Barros, Xoana|||0000-0001-9690-9769
  • Marco Rusiñol, Helena|||0000-0002-7229-8729
  • Navarro Diaz, Maruja Isabel|||0000-0003-3001-0595
  • Esparza, Noemí
  • Elias, Sandra
  • Coloma, Ana|||0000-0002-1773-9560
  • Robles, Nicolás Roberto|||0000-0003-4984-6691
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Poch, Esteban|||0000-0002-6492-024X
  • Rodas, Lidia
  • Lozano, Víctor
  • Fernández-Fernández, Beatriz
  • Hernández, Eduardo
  • Martínez, Maria Isabel
  • Stanescu, Ramona Ionela
  • Moirón, José Pelayo
  • García Fernández, Nuria|||0000-0003-1082-0806
  • Goicoechea, Marian|||0000-0002-7614-0830
  • Calero, Francesca|||0000-0002-5758-0769
  • Bonet Sol, Josep
  • Liaño, Fernando
  • Pascual, Julio|||0000-0002-4735-7838
  • Bestard Matamoros, Oriol|||0000-0001-9468-7920
  • Praga, Manuel|||0000-0001-9270-1071
  • Fulladosa, Xavier|||0000-0003-1974-9874
  • Soler, María José|||0000-0003-3621-0766
Up to 50-60% of patients with diabetes have non-diabetic kidney disease (NDKD) on kidney biopsy. Diabetic retinopathy (DR) is a microvascular complication of diabetes frequently associated with diabetic nephropathy (DN). The objective of the current study was to investigate the kidney outcomes and survival in patients with biopsy diagnoses of DN and NDKD according to the presence of DR. We conducted an observational, multicentre and retrospective study of the pathological findings of renal biopsies from 832 consecutive patients with diabetes from 2002 to 2014 from 18 nephrology departments. The association of DR with kidney replacement therapy (KRT) or survival was assessed by Kaplan-Meier and Cox regression analyses. Of 832 patients with diabetes and renal biopsy, 768 had a retinal examination and 221/768 (22.6%) had DR. During a follow-up of 10 years, 288/760 (37.9%) patients with follow-up data needed KRT and 157/760 (20.7%) died. The incidence of KRT was higher among patients with DN (alone or with NDKD) and DR [103/175 (58.9%)] than among patients without DR [88/216 (40.7%), P <.0001]. The incidence of KRT was also higher among patients with only NDKD and DR than among those without DR [18/46 (39.1%) versus 79/331 (23.9%), P <.0001]. In multivariate analysis, DR or DN were independent risk factors for KRT {hazard ratio [HR] 2.48 [confidence interval (CI) 1.85-3.31], P <.001}. DN (with or without DR) was also identified as an independent risk factor for mortality [HR 1.81 (CI 1.26-2.62), P =.001]. DR is associated with a higher risk of progression to kidney failure in patients with histological DN and in patients with NDKD.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Immunotherapy and the Spectrum of Kidney Disease: Should We Individualize the Treatment?

  • Bermejo Garcia, Sheila
  • Bolufer Cardona, Monica
  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
Chronic kidney disease; Dialysis; Immunotherapy, Enfermedad renal cronica; Diálisis; Inmunoterapia, Malaltia renal crònica; Diàlisi; Immunoteràpia, The new targeted cancer therapies including immune checkpoint inhibitors (ICIs) have been demonstrated to improve the survival of oncological patients, even in cases of metastatic cancer. In the past 5 years, several studies have revealed that ICI can produce several immune-mediated toxicities involving different organs, such as the skin, the gastrointestinal tract, the liver, and, of course, the kidney. The most frequent lesion of immunotoxicity in the kidney is acute interstitial nephritis (AIN), although other nephropathies have also been described as a consequence of the use of ICI, such as glomerulonephritis and acute thrombotic microangiopathy, among others. In addition, kidney rejection has also been reported in kidney transplant patients treated with ICI. Normally randomized clinical trials with ICI exclude patients with end-stage kidney disease, namely, patients undergoing dialysis and kidney transplant patients. Several important questions need to be addressed in relation to immunotherapy and patients with kidney disease: (a) when to start corticosteroid therapy in a patient with suspected acute kidney injury (AKI) related to ICI, (b) the moment of nephrologist referral and kidney biopsy indication, (c) management of ICI in patients undergoing dialysis, and (d) the effect of ICI in kidney transplantation, immunosuppressive personalized treatment, and risk of allograft rejection in kidney transplant patients. The objective of this review was to summarize the recently published literature on a wide spectrum of kidney disease patients with cancer and ICI. This review will address three main important groups of individuals with kidney disease and cancer immunotherapy, AKI associated with ICI, patients undergoing dialysis, and kidney transplant recipients. We believe that the information provided in this review will enlighten the personalized ICI treatment in individuals with a broader spectrum of kidney diseases., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, Grant Numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

COVID-19 infection and renal injury: where is the place for acute interstitial nephritis disease?

  • León Román, Juan
  • Agraz Pamplona, Irene
  • Vergara Arana, Ander
  • Toapanta Gaibor, Nestor Gabriel
  • García Carro, Clara
  • Gabaldon Dominguez, Alejandra
  • Roxana Bury Macias, Roxana Paola
  • Bermejo Garcia, Sheila
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
  • Ramos Terrades, Natalia
COVID-19; Nefritis tubulointersticial aguda; Biòpsia de ronyó, COVID-19; Nefritis tubulointersticial aguda; Biopsia de riñón, COVID-19; Acute tubulointerstitial nephritis; Kidney biopsy, Novel coronavirus disease infection (coronavirus disease 2019, COVID-19) was declared a global pandemic in March 2020 and since then has become a major public health problem. The prevalence of COVID-19 infection and acute kidney injury (AKI) is variable depending on several factors such as race/ethnicity and severity of illness. The pathophysiology of renal involvement in COVID-19 infection is not entirely clear, but it could be in part explained by the viral tropism in the kidney parenchyma. AKI in COVID-19 infection can be either by direct invasion of the virus or as a consequence of immunologic response. Diverse studies have focused on the effect of COVID-19 on glomerulonephritis (GN) patients or the ‘novo’ GN; however, the effect of COVID-19 in acute tubulointerstitial nephritis (ATIN) has been scarcely studied. In this article, we present five cases with different spectrums of COVID-19 infection and ATIN that may suggest that recent diagnosis of ATIN is accompanied by a worse clinical prognosis in comparison with long-term diagnosed ATIN., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN, grant number PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016. Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR), enfermedades glomerulares complejas.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Challenges in primary focal segmental glomerulosclerosis diagnosis: from the diagnostic algorithm to novel biomarkers

  • Jacobs Cachá, Concepció
  • Vergara Arana, Ander
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
  • López Hellin, Joan
  • Soler Romeo, Maria Jose
  • Ariceta Iraola, Gema
Biomarcadors; Algoritme de diagnosi; Glomerulosclerosi segmentària focal, Biomarcadores; Algoritmo de diagnóstico; Glomeruloesclerosis segmentaria focal, Biomarkers; Diagnosis algorithm; Focal segmental glomerulosclerosis, Primary or idiopathic focal segmental glomerulosclerosis (FSGS) is a kidney entity that involves the podocytes, leading to heavy proteinuria and in many cases progresses to end-stage renal disease. Idiopathic FSGS has a bad prognosis, as it involves young individuals who, in a considerably high proportion (∼15%), are resistant to corticosteroids and other immunosuppressive treatments as well. Moreover, the disease recurs in 30–50% of patients after kidney transplantation, leading to graft function impairment. It is suspected that this relapsing disease is caused by a circulating factor(s) that would permeabilize the glomerular filtration barrier. However, the exact pathologic mechanism is an unsettled issue. Besides its poor outcome, a major concern of primary FSGS is the complexity to confirm the diagnosis, as it can be confused with other variants or secondary forms of FSGS and also with other glomerular diseases, such as minimal change disease. New efforts to optimize the diagnostic approach are arising to improve knowledge in well-defined primary FSGS cohorts of patients. Follow-up of properly classified primary FSGS patients will allow risk stratification for predicting the response to different treatments. In this review we will focus on the diagnostic algorithm used in idiopathic FSGS both in native kidneys and in disease recurrence after kidney transplantation. We will emphasize those potential confusing factors as well as their detection and prevention. In addition, we will also provide an overview of ongoing studies that recruit large cohorts of glomerulopathy patients (Nephrotic Syndrome Study Network and Cure Glomerulonephropathy, among others) and the experimental studies performed to find novel reliable biomarkers to detect primary FSGS., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, Instituto de Salud Carlos III (PI17/00257, PI18/01704 and PI18/01832) and REDinREN (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Safety of Obtaining an Extra Biobank Kidney Biopsy Core

  • Bermejo Garcia, Sheila
  • García Carro, Clara
  • Mast, Richard
  • Vergara Arana, Ander
  • Agraz Pamplona, Irene
  • León Román, Juan
  • Bolufer Cardona, Monica
  • Gabaldon Dominguez, Alejandra
  • Serón Micas, Daniel
  • Bestard Matamoros, Oriol
  • Soler Romeo, Maria Jose
Biobank; Chronic kidney disease; Kidney biopsy, Biobanco; Enfermedad renal cronica; Biopsia renal, Biobanc; Malaltia renal crònica; Biòpsia de ronyó, Background and objectives: Kidney biopsy (KB) is the “gold standard” for the diagnosis of nephropathies and it is a diagnostic tool that presents a low rate of complications. Nowadays, biobank collections of renal tissue of patients with proven renal pathology are essential for research in nephrology. To provide enough tissue for the biobank collection, it is usually needed to obtain an extra kidney core at the time of kidney biopsy. The objective of our study is to evaluate the complications after KB and to analyze whether obtaining an extra core increases the risk of complications. Material and methods: Prospective observational study of KBs performed at Vall d’Hebron Hospital between 2019 and 2020. All patients who accepted to participate to our research biobank of native kidney biopsies were included to the study. Clinical and laboratory data were reviewed and we studied risk factors associated with complications. Results: A total of 221 patients were included, mean age 56.6 (±16.8) years, 130 (58.8%) were men, creatinine was 2.24 (±1.94) mg/dL, proteinuria 1.56 (0.506–3.590) g/24 h, hemoglobin 12.03 (±2.3) g/dL, INR 0.99 (±0.1), and prothrombin time (PT) 11.86 (±1.2) s. A total of 38 patients (17.2%) presented complications associated with the procedure: 13.1% were minor complications, 11.3% (n = 25) required blood transfusion, 1.4% (n = 3) had severe hematomas, 2.3% (n = 5) required embolization, and 0.5% (n = 1) presented arterio-venous fistula. An increased risk for complication was independently associated with obtaining a single kidney core (vs. 2 and 3 cores) (p = 0.021). Conclusions: KB is an invasive and safe procedure with a low percentage of complications. Obtaining an extra kidney core for research does not increase the risk of complications during the intervention, which remains low in concordance with previously published reports., The authors are current recipients of research grant from Red de Investigación Renal (REDINREN, RD16/0009/0030). (RICORS, RD21/0005/0016).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Expert Clinical Management of Severe Immune-Related Adverse Events: Results from a Multicenter Survey on Hot Topics for Management

  • Riveiro Barciela, Maria del Mar
  • Soler Romeo, Maria Jose
  • Barreira Diaz, Ana
  • Bermejo Garcia, Sheila
  • Suarez-Almazor, Maria
  • Bruera, Sebastian
Acute kidney injury; Immune checkpoint inhibitors; Immune-related hepatitis, Lesión renal aguda; Inhibidores del punto de control inmunitario; Hepatitis relacionada con el sistema inmunitario, Lesió renal aguda; Inhibidors del punt de control immunitari; Hepatitis associada a la immunitat, There are differences in recommendations for the management of immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs). To assess the real-world management of irAEs, three surveys regarding ICI-induced hepatitis (IIH), renal irAEs, and myositis were developed and sent to experts in each area. Fifty-six surveys were completed (17 IIH, 20 renal irAEs, and 19 myositis). All experts agreed on performing imaging in every suspected case of severe IIH. Sixty-five percent agreed on performing a liver biopsy in patients not responding to corticosteroids. The most common indication for corticosteroid use (59%) was for severe IIH not improving after discontinuation of ICIs. Additionally, 60% of the experts agreed on performing a biopsy for stage 2/3 acute kidney injury (AKI), and 70% recommended imaging for any stage of AKI. Thirty-five percent favored corticosteroids in AKI patients with creatinine levels 2–3-fold above baseline. For myositis, 58% would recommend a muscle biopsy in a patient with weakness and creatine kinase levels of 5000 U/L; 47% would also opt for an endomyocardial biopsy when the troponin levels are increased. Fifty-eight percent recommended oral corticosteroids for myositis, and 37% recommended additional therapy, mainly immunoglobulins. These results show substantial differences in expert practice patterns for the management of severe liver, kidney, and muscular irAEs., This research was funded by ISCIIII-FEDER and ISCIII-RETICS REDinREN (grant numbers PI17/00257, PI21/01292, RD16/0009/0030, and RICORS RD21/0005/0016) and Enfermedad Glomerular Compleja del Sistema Nacional de Salud (CSUR) enfermedades glomerulares complejas. Supported in part by the University of Texas MD Anderson’s Cancer Center Support Grant from the National Cancer Institute (NCI P30 CA016672).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Progression of Interstitial Fibrosis and Tubular Atrophy in Low Immunological Risk Renal Transplants Monitored by Sequential Surveillance Biopsies: The Influence of TAC Exposure and Metabolism

  • Chamoun Huacon, Betty Odette
  • Torres Rodriguez, Irina Betsabe
  • Gabaldon Dominguez, Alejandra
  • Sellarés Roig, Joana
  • Perelló Carrascosa, Manel
  • Castella Fierro, Eva
  • Guri Azogue, Xavier
  • Salcedo Allende, Maria Teresa
  • Toapanta Gaibor, Nestor Gabriel
  • Cidraque Vella, Ignacio
  • Moreso Mateos, Francesc
  • Serón Micas, Daniel
Coeficient de variació; Biòpsies de protocol; Trasplantament renal, Coeficiente de variación; Biopsias de protocolo; Trasplante renal, Coefficient of variation; Protocol biopsies; Renal transplantation, The combination of tacrolimus (TAC) and mycophenolate is the most widely employed maintenance immunosuppression in renal transplants. Different surrogates of tacrolimus exposure or metabolism such as tacrolimus trough levels (TAC-C0), coefficient of variation of tacrolimus (CV-TAC-C0), time in therapeutic range (TTR), and tacrolimus concentration dose ratio (C/D) have been associated with graft outcomes. We explore in a cohort of low immunological risk renal transplants (n = 85) treated with TAC, mycophenolate mofetil (MMF), and steroids and then monitored by paired surveillance biopsies the association between histological lesions and TAC-C0 at the time of biopsy as well as CV-TAC-C0, TTR, and C/D during follow up. Interstitial inflammation (i-Banff score ≥ 1) in the first surveillance biopsy was associated with TAC-C0 (odds ratio (OR): 0.69, 95% confidence interval (CI): 0.50–0.96; p = 0.027). In the second surveillance biopsy, inflammation was associated with time below the therapeutic range (OR: 1.05 and 95% CI: 1.01–1.10; p = 0.023). Interstitial inflammation in scarred areas (i-IFTA score ≥ 1) was not associated with surrogates of TAC exposure/metabolism. Progression of interstitial fibrosis/tubular atrophy (IF/TA) was observed in 35 cases (41.2%). Multivariate regression logistic analysis showed that mean C/D (OR: 0.48; 95% CI: 0.25–0.92; p = 0.026) and IF/TA in the first biopsy (OR: 0.43, 95% CI: 0.24–0.77, p = 0.005) were associated with IF/TA progression between biopsies. A low C/D ratio is associated with IF/TA progression, suggesting that TAC nephrotoxicity may contribute to fibrosis progression in well immunosuppressed patients. Our data support that TAC exposure is associated with inflammation in healthy kidney areas but not in scarred tissue., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030), Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382), the Spanish Society of Transplantation and a Diaverum Spain restricted grant. Betty Chamoun has been supported by a VHIR (Vall Hebron Institute Research) grant.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Kidney Biopsy in Patients with Cancer along the Last Decade: A Multicenter Study

  • Bolufer Cardona, Monica
  • Blasco, Miquel
  • Quintana, Luis F
  • Rabasco, Cristina
  • Shabaka, Amir
  • García-Carro, Clara
Kidney biopsy; Renal pathology; Solid organ neoplasm, Biòpsia renal; Patologia renal; Neoplàsia d'òrgans sòlids, Biopsia renal; Patología renal; Neoplasia de órganos sólidos, Background: Currently, following the new advances in cancer treatments and the increasing prevalence of kidney disease in the population, more kidney biopsies are being performed. The aim of our study is to analyze clinical and histological characteristics of patients with active solid organ malignancy who underwent kidney biopsy. This is a multi-center collaborative retrospective study supported by groups GLOSEN/Onconephrology from the Spanish Society of Nephrology. Clinical, demographical and histological data were collected. Results: A total of 148 patients with cancer who underwent a kidney biopsy from 12 hospitals were included. 64.3% men and mean age of 66.9 years old. The indications for biopsy were acute renal injury (67.1%), proteinuria (17.1%), exacerbated chronic kidney disease (8.2%), and chronic kidney disease (7.5%). Most frequent malignances were lung (29.1%) and abdominal (25%), with 49.7% metastatic cancer. As oncospecific treatment, 28% received chemotherapy, 29.3% immunotherapy, 19.3% specific therapies, and 2.1% conservative treatment. At the time of kidney biopsy, median creatinine was of 2.58 mg/dL [1.81–4.1 (IQ 25–75)], median urine protein-to-creatinine ratio of 700 mg/g [256–2463 (IQ 25–75)] and 53.1% presented hematuria. The most frequent renal biopsy diagnoses were: acute interstitial nephritis (39.9%), acute tubular necrosis (8.8%), IgA nephropathy (7.4%) and membranous nephropathy (6.1%). Median follow-up was 15.2 months [5.7–31.4 (IQ 25–75)]. Conclusions: There is a new trend in kidney disease and cancer patients in terms of diagnosis and treatment. Acute interstitial nephritis has established itself as the most common kidney injury in patients with cancer who underwent a kidney biopsy. Renal biopsy is a valuable tool for diagnosis, treatment, and prognosis of solid organ cancer patients with kidney damage., This work was supported by grants from Fondo de Investigación Sanitaria-FEDER, ISCIII, Río Hortega CM20/00111, PI17/00257, PI21/01292, Marató TV3 2020 421/C/2020, Marató TV3 2021 215/C/2021, RD16/0009/0030 (REDINREN), EIN2020-1123381, and RD21/0005/0016 (RICORS 2040).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

COVID-19 in CKD Patients: Lessons from 553 CKD Patients with Biopsy-Proven Kidney Disease

  • León Román, Juan
  • García Carro, Clara
  • Agraz Pamplona, Irene
  • Toapanta Gaibor, Nestor Gabriel
  • Vergara Arana, Ander
  • Gabaldon Dominguez, Alejandra
  • Torres Rodriguez, Irina Betsabe
  • Bury, Roxana
  • Baldallo, Cinthia
  • Serón Micas, Daniel
  • Soler Romeo, Maria Jose
COVID-19; Malaltia renal crònica, COVID-19; Enfermedad renal crónica, COVID-19; Chronic kidney disease, Introduction: Chronic kidney disease (CKD) patients infected with COVID-19 are at risk of serious complications such as hospitalization and death. The prognosis and lethality of COVID-19 infection in patients with established kidney disease has not been widely studied. Methods: Data included patients who underwent kidney biopsy at the Vall d’Hebron Hospital between January 2013 and February 2020 with COVID-19 diagnosis during the period from March 1 to May 15, 2020. Results: Thirty-nine (7%) patients were diagnosed with COVID-19 infection. Mean age was 63 ± 15 years and 48.7% were male. Hypertension was present in 79.5%, CKD without renal replacement therapy in 76.9%, and cardiovascular disease in 64.1%. Nasopharyngeal swab was performed in 26 patients; older (p = 0.01), hypertensive (p = 0.005), and immunosuppressed (p = 0.01) patients, those using RAS-blocking drugs (p = 0.04), and those with gastrointestinal symptoms (p = 0.02) were more likely to be tested for CO­VID-19. Twenty-two patients required hospitalization and 15.4% died. In bivariate analysis, mortality was associated with older age (p = 0.03), cardiovascular disease (p = 0.05), chronic obstructive pulmonary disease (p = 0.05), and low hemoglobin levels (p = 0.006). Adjusted Cox regression showed that low hemoglobin levels at admission had 1.81 greater risk of mortality. Conclusions: Patients with CO­VID-19 infection and kidney disease confirmed by kidney biopsy presented a mortality of 15.4%. Swab test for COVID-19 was more likely to be performed in older, hypertensive, and immunosuppressed patients, those using RAS-blocking drugs, and those with gastrointestinal symptoms. Low hemoglobin is a risk factor for mortality., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder (FI17/00257 and EIN2020-1123381) and Redinren (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience

  • Oleas, Diana
  • Bolufer Cardona, Monica
  • Agraz Pamplona, Irene
  • Gabaldon Dominguez, Alejandra
  • Bury, Roxana
  • Espinel Garuz, María Eugenia
  • Serón Micas, Daniel
  • García Carro, Clara
  • Soler Romeo, Maria Jose
  • Muñoz Couselo, Eva
  • Felip Font, Enriqueta
Nefritis intersticial aguda; Inhibidors de punts de control; Biòpsia de ronyó, Nefritis intersticial aguda; Inhibidores de puntos de control; Biopsia renal, Acute interstitial nephritis; Checkpoint inhibitors; Kidney biopsy, Background Checkpoint inhibitors (CPIs) are used to treat solid organ metastatic malignancies. They act by triggering a vigorous immune response against tumoural cells, preventing their proliferation and metastasis. However, this is not a selective response and can cause immune-related adverse events (irAEs). The kidney can potentially be damaged, with an incidence of irAEs of 1–4%. The most frequent type of toxicity described is acute interstitial nephritis (AIN). Methods We conducted a study of patients with solid organ metastatic malignancies treated with immunotherapy who developed acute renal injury and underwent kidney biopsy in the last 14 months at the Vall d’Hebron University Hospital. Results In all, 826 solid organ malignancies were treated with immunotherapy in our centre, 125 of them (15.1%) developed acute kidney injury (AKI), 23 (18.4% of AKI) visited the nephrology department and 8 underwent kidney biopsy. The most frequent malignancy was lung cancer, in five patients (62%), followed by two patients (25%) with melanoma and one patient (12%) with pancreatic cancer. Four patients (50%) had already received previous oncological therapy, and for the remaining four patients (50%), CPI was the first-line therapy. Five patients (62%) were treated with anti-programmed cell death protein 1, three patients (37%) received anti-programmed death ligand 1 and two (25%) patients were treated in combination with anti-cytotoxic T-lymphocyte antigen 4. The time between the start of CPI and the onset of the AKI ranged from 2 to 11 months. The most frequent urine findings were subnephrotic-range proteinuria, with a mean protein:creatinine ratio of 544 mg/g (standard deviation 147) and eosinophiluria. All patients were biopsied after being diagnosed with AIN. Three patients (37%) received treatment with pulses of methylprednisolone 250–500 mg/day and five patients (62%) received prednisone 1 mg/kg/day. Seven patients (87%) experienced recovery of kidney function and one patient (12%) progressed to chronic kidney disease. Conclusions We report on eight patients with CPI-related AIN diagnosed in the last 14 months at our centre. The novel immunotherapy treatment of metastatic solid organ malignancies carries a higher risk of irAEs. The kidney is one of the most commonly affected organs, frequently presenting as an AIN and exhibiting a favourable response to steroid treatment., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder, ISCIII (PI17/00257) and Redinren (RD16/0009/0030). M.B. performed this work as the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Kidney transplantation and COVID-19 renal and patient prognosis

  • Toapanta Gaibor, Nestor Gabriel
  • Torres Rodriguez, Irina Betsabe
  • Sellarés Roig, Joana
  • Chamoun Huacon, Betty Odette
  • Serón Micas, Daniel
  • Moreso Mateos, Francesc
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultat respiratòria aguda; Trasplantament renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Síndrome de dificultad respiratoria aguda; Trasplante renal, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Acute respiratory distress syndrome; Renal transplantation, Coronavirus disease 2019 (COVD-19) emerged as a pandemic in December 2019. Infection has spread quickly and renal transplant recipients receiving chronic immunosuppression have been considered a population at high risk of infection, complications and infection-related death. During this year a large amount of information from nationwide registries, multicentre and single-centre studies have been reported. The number of renal transplant patients diagnosed with COVID-19 was higher than in the general population, but the lower threshold for testing may have contributed to its better identification. Major complications such as acute kidney injury and acute respiratory distress syndrome were very frequent in renal transplant patients, with a high comorbidity burden, but further studies are needed to support that organ transplant recipients receiving chronic immunosuppression are more prone to develop these complications than the general population. Kidney transplant recipients experience a high mortality rate compared with the general population, especially during the very early post-transplant period. Despite the fact that some studies report more favourable outcomes in patients with a kidney transplant than in patients on the kidney waiting list, the higher mortality described in the very early post-transplant period would advise against performing a kidney transplant in areas where the spread of infection is high, especially in recipients >60 years of age. Management of transplant recipients has been challenging for clinicians and strategies such as less use of lymphocyte-depleting agents for new transplants or anti-metabolite withdrawal and calcineurin inhibitor reduction for transplant patients with COVID-19 are not based on high-quality evidence., The authors received grants from Red de Investigación Renal (REDinREN RD16/0009/0030) and Fondo de Investigación Sanitaria del Instituto de Salud Carlos III (PI 18/01704, PI 18/01382). B.C. is supported by a Vall d’Hebron Institute of Research grant. This article is part of a supplement supported by Fresenius Medical Care without any influence on its content.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

How to Assess Diabetic Kidney Disease Progression? From Albuminuria to GFR

  • Vergara Arana, Ander
  • Bermejo Garcia, Sheila
  • Azancot Rivero, M Antonieta
  • Sanchez Fructuoso, Ana Isabel
  • Sánchez de la Nieta, M. Dolores
  • Agraz Pamplona, Irene
  • Soler Romeo, Maria Jose
  • García-Carro, Clara
Malaltia renal crònica; Diabetis mellitus; Malaltia renal diabètica, Enfermedad renal crónica; Diabetes mellitus; Enfermedad renal diabética, Chronic kidney disease; Diabetes mellitus; Diabetic kidney disease, Diabetic kidney disease (DKD) is one of the most relevant complications of type 2 diabetes and dramatically increases the cardiovascular risk in these patients. Currently, DKD is severely infra-diagnosed, or its diagnosis is usually made at advanced stages of the disease. During the last decade, new drugs have demonstrated a beneficial effect in terms of cardiovascular and renal protection in type 2 diabetes, supporting the crucial role of an early DKD diagnosis to permit the use of new available therapeutic strategies. Moreover, cardiovascular and renal outcome trials, developed to study these new drugs, are based on diverse cardiovascular and renal simple and composite endpoints, which makes difficult their interpretation and the comparison between them. In this article, DKD diagnosis is reviewed, focusing on albuminuria and the recommendations for glomerular filtration rate measurement. Furthermore, cardiovascular and renal endpoints used in classical and recent cardiovascular outcome trials are assessed in a pragmatic way., The authors are current recipients of research grants from the Fondo de Investigación Sanitaria-Feder—Instituto de Salud Carlos III (PI17/00257) and REDinREN (RD16/0009/0030).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

The Impact of Age on Mortality in Chronic Haemodialysis Population with COVID-19

  • Vergara Arana, Ander
  • Molina Van den Bosch, Mireia
  • Toapanta Gaibor, Nestor Gabriel
  • Villegas, Andrés
  • Sánchez-Cámara, Luis
  • Soler Romeo, Maria Jose
  • de Sequera, Patricia
Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiàlisi; Mortalitat, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Hemodiálisis; Mortalidad, Coronavirus SARS-CoV-2; COVID-19; 2019-nCoV; Haemodialysis; Mortality, Age and chronic kidney disease have been described as mortality risk factors for coronavirus disease 2019 (COVID-19). Currently, an important percentage of patients in haemodialysis are elderly. Herein, we investigated the impact of age on mortality among haemodialysis patients with COVID-19. Data was obtained from the Spanish COVID-19 chronic kidney disease (CKD) Working Group Registry. From 18 March 2020 to 27 August 2020, 930 patients on haemodialysis affected by COVID-19 were included in the Registry. A total of 254 patients were under 65 years old and 676 were 65 years or older (elderly group). Mortality was 25.1% higher (95% CI: 22.2–28.0%) in the elderly as compared to the non-elderly group. Death from COVID-19 was increased 6.2-fold in haemodialysis patients as compared to the mortality in the general population in a similar time frame. In the multivariate Cox regression analysis, age (hazard ratio (HR) 1.59, 95% CI: 1.31–1.93), dyspnea at presentation (HR 1.51, 95% CI: 1.11–2.04), pneumonia (HR 1.74, 95% CI: 1.10–2.73) and admission to hospital (HR 4.00, 95% CI: 1.83–8.70) were identified as independent mortality risk factors in the elderly haemodialysis population. Treatment with glucocorticoids reduced the risk of death (HR 0.68, 95% CI: 0.48–0.96). In conclusion, mortality is dramatically increased in elderly haemodialysis patients with COVID-19. Our results suggest that this high risk population should be prioritized in terms of protection and vaccination., The authors are current recipients of FONDOS DE INVESTIGACIÓN SANITARIA—FEDER (ISCIII) PI17/00257, REDINREN RD16/0009/0030, RD/16/0009/0026, and EIN2020-112338.